作者：刘辉&罗素素“医生说我不能手术，是不是就没救了？”答案是：不是。手术切除固然是治愈肝癌的首选，但它并不是唯一的武器。对很多不能手术的患者来说，真正延长生命、控制病情的关键，往往来自刀口之外的疗法：消融、介入、靶向、免疫、放射，一起组成了肝癌治疗 ...

中国单细胞与空间组学系列论坛3月24日，中山大学/澳门大学研究团队在期刊《Journal for ImmunoTherapy of Cancer》上发表了研究论文，题为“Targeted inhibition of Nrf2 potentiates ...

This review explores the dynamic landscape of hepatocellular carcinoma (HCC) treatment, emphasizing on recent developments across various stages and therapeutic approaches. Although curative ...

Second-line regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) after progression on first-line atezolizumab plus bevacizumab (Atezo-Bev): Phase 2 REGONEXT trial. Clinical ...

A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test results ...

DelveInsight’s, “Hepatic Tumor Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and ...

Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and one of the leading causes of cancer-related deaths worldwide. Early detection and accurate diagnosis are crucial for effective ...

Long-term use of statins may delay or deflect the development of hepatocellular carcinoma in adults with chronic liver disease, as well as in the general population, emerging research, including ...